Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma

Letter to the Editor


Author contributions

Hugo J.A. Adams: study design, article writing, final approval of the manuscript.

Thomas C. Kwee: study design, article writing, final approval of the manuscript.

Compliance with ethical standards

Conflicts of interest





  1. 1.
    Hindie E, Mesguich C, Bouabdallah K, Milpied N. Advanced Hodgkin's lymphoma: end-of-treatment FDG-PET should be maintained. Eur J Nucl Med Mol Imaging. 2017; doi: 10.1007/s00259-017-3714-4.
  2. 2.
    Press OW, Li H, Schoder H, Straus DJ, Moskowitz CH, LeBlanc M, et al. US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim Fluorodeoxyglucose-positron emission tomography imaging: southwest oncology group S0816. J Clin Oncol. 2016; doi: 10.1200/JCO.2015.63.1119.
  3. 3.
    Johnson P, Federico M, Kirkwood A, Fossa A, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016;374:2419–29. doi: 10.1056/NEJMoa1510093.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, et al. Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol. 2016;34:1376–85. doi: 10.1200/JCO.2015.63.0699.CrossRefPubMedGoogle Scholar
  5. 5.
    Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52. doi: 10.1200/JCO.2007.11.6525.CrossRefPubMedGoogle Scholar
  6. 6.
    Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica. 2014;99:1107–13. doi: 10.3324/haematol.2013.103218.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Mesguich C, Cazeau AL, Bouabdallah K, Soubeyran P, Guyot M, Milpied N, et al. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation. Br J Haematol. 2016;175:652–60. doi: 10.1111/bjh.14292.CrossRefPubMedGoogle Scholar
  8. 8.
    Zinzani PL, Rigacci L, Stefoni V, Broccoli A, Puccini B, Castagnoli A, et al. Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging. 2012;39:4–12. doi: 10.1007/s00259-011-1916-8.CrossRefPubMedGoogle Scholar
  9. 9.
    Adams HJ, Kwee TC. Predictive value of interim [18F]Fluorodeoxyglucose-positron emission tomography in advanced-stage Hodgkin lymphoma is not well established. J Clin Oncol. 2017;35:370–1. doi: 10.1200/JCO.2016.68.1494.CrossRefPubMedGoogle Scholar
  10. 10.
    Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, et al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin study group. Lancet Oncol. 2017;18:454–63. doi: 10.1016/S1470-2045(17)30103-1.CrossRefPubMedGoogle Scholar
  11. 11.
    Bakhshi S, Bhethanabhotla S, Kumar R, Agarwal K, Sharma P, Thulkar S, et al. Posttreatment PET/CT rather than interim PET/CT using Deauville criteria predicts outcome in pediatric Hodgkin lymphoma: a prospective study comparing PET/CT with conventional imaging. J Nucl Med. 2017;58:577–83. doi: 10.2967/jnumed.116.176511.CrossRefPubMedGoogle Scholar
  12. 12.
    Barnes JA, LaCasce AS, Zukotynski K, Israel D, Feng Y, Neuberg D, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. Ann Oncol. 2011;22:910–5. doi: 10.1093/annonc/mdq549.CrossRefPubMedGoogle Scholar
  13. 13.
    Cerci JJ, Pracchia LF, Linardi CC, Pitella FA, Delbeke D, Izaki M, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med. 2010;51:1337–43. doi: 10.2967/jnumed.109.073197.CrossRefPubMedGoogle Scholar
  14. 14.
    Filippi AR, Botticella A, Bello M, Botto B, Castiglione A, Gavarotti P, et al. Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy. Leuk. Lymphoma. 2013;54:1183–7. doi: 10.3109/10428194.2012.735667.CrossRefPubMedGoogle Scholar
  15. 15.
    Jalali A, Ha FJ, Chong G, Grigg A, McKendrick J, Schwarer AP, et al. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era. Ann Hematol. 2016;95:809–16. doi: 10.1007/s00277-016-2611-4.CrossRefPubMedGoogle Scholar
  16. 16.
    Lopci E, Burnelli R, Guerra L, Cistaro A, Piccardo A, Zucchetta P, et al. Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease. Eur J Nucl Med Mol Imaging. 2011;38:1620–7. doi: 10.1007/s00259-011-1836-7.CrossRefPubMedGoogle Scholar
  17. 17.
    Markova J, Kahraman D, Kobe C, Skopalova M, Mocikova H, Klaskova K, et al. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leuk. Lymphoma. 2012;53:64–70. doi: 10.3109/10428194.2011.603444.CrossRefPubMedGoogle Scholar
  18. 18.
    Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, et al. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011;117:5314–20. doi: 10.1182/blood-2010-10-314260.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Adams HJ, Kwee TC. Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: systematic review and meta-analysis. Eur J Radiol. 2016;85:1963–70. doi: 10.1016/j.ejrad.2016.08.011.CrossRefPubMedGoogle Scholar
  20. 20.
    Pileri SA, Ascani S, Leoncini L, Sabattini E, Zinzani PL, Piccaluga PP, et al. Hodgkin's lymphoma: the pathologist's viewpoint. J Clin Pathol. 2002;55:162–76.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Jakobsen LH, Hutchings M, de Nully Brown P, Linderoth J, Mylam KJ, Molin D, et al. No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study. Br J Haematol. 2016;173:236–44. doi: 10.1111/bjh.13943.CrossRefPubMedGoogle Scholar
  22. 22.
    Goldschmidt N, Or O, Klein M, Savitsky B, Paltiel O. The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Ann Hematol. 2011;90:165–71. doi: 10.1007/s00277-010-1044-8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Department of Radiology and Nuclear MedicineDeventer ZiekenhuisDeventerThe Netherlands
  2. 2.Department of Radiology, Nuclear Medicine and Molecular ImagingUniversity Medical Center Groningen, University of GroningenGroningenThe Netherlands

Personalised recommendations